These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 20489063)
1. Role of PET/CT in ovarian cancer. Prakash P; Cronin CG; Blake MA AJR Am J Roentgenol; 2010 Jun; 194(6):W464-70. PubMed ID: 20489063 [TBL] [Abstract][Full Text] [Related]
2. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy. Fagotti A; Fanfani F; Rossitto C; Lorusso D; De Gaetano AM; Giordano A; Vizzielli G; Scambia G Oncology; 2008; 75(3-4):152-8. PubMed ID: 18827492 [TBL] [Abstract][Full Text] [Related]
3. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients. Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344 [TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose. Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554 [TBL] [Abstract][Full Text] [Related]
5. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer. Cho SM; Ha HK; Byun JY; Lee JM; Kim CJ; Nam-Koong SE; Lee JM AJR Am J Roentgenol; 2002 Aug; 179(2):391-5. PubMed ID: 12130439 [TBL] [Abstract][Full Text] [Related]
6. Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment. Picchio M; Sironi S; Messa C; Mangili G; Landoni C; Gianolli L; Zangheri B; Viganò R; Aletti G; De Marzi P; De Cobelli F; Del Maschio A; Ferrari A; Fazio F Q J Nucl Med; 2003 Jun; 47(2):77-84. PubMed ID: 12865867 [TBL] [Abstract][Full Text] [Related]
7. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Thrall MM; DeLoia JA; Gallion H; Avril N Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284 [TBL] [Abstract][Full Text] [Related]
8. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET. Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219 [TBL] [Abstract][Full Text] [Related]
9. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques. Aukema TS; Rutgers EJ; Vogel WV; Teertstra HJ; Oldenburg HS; Vrancken Peeters MT; Wesseling J; Russell NS; Valdés Olmos RA Eur J Surg Oncol; 2010 Apr; 36(4):387-92. PubMed ID: 19962268 [TBL] [Abstract][Full Text] [Related]
10. Novel perioperative imaging with 18F-FDG PET/CT and intraoperative 18F-FDG detection using a handheld gamma probe in recurrent ovarian cancer. Cohn DE; Hall NC; Povoski SP; Seamon LG; Farrar WB; Martin EW Gynecol Oncol; 2008 Aug; 110(2):152-7. PubMed ID: 18539314 [TBL] [Abstract][Full Text] [Related]
11. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Yen RF; Sun SS; Shen YY; Changlai SP; Kao A Anticancer Res; 2001; 21(5):3691-4. PubMed ID: 11848544 [TBL] [Abstract][Full Text] [Related]
12. [The value of FDG PET/CT, ultrasound and CT in diagnosing recurrent ovarian carcinoma]. Grabiec M; Walentowicz M; Nowicki P Ginekol Pol; 2006 Oct; 77(10):746-52. PubMed ID: 17219805 [TBL] [Abstract][Full Text] [Related]
13. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Nanni C; Rubello D; Farsad M; De Iaco P; Sansovini M; Erba P; Rampin L; Mariani G; Fanti S Eur J Surg Oncol; 2005 Sep; 31(7):792-7. PubMed ID: 15893908 [TBL] [Abstract][Full Text] [Related]
14. FDG PET/CT in the detection of recurrent rectal cancer. Kau T; Reinprecht P; Eicher W; Lind P; Starlinger M; Hausegger KA Int Surg; 2009; 94(4):315-24. PubMed ID: 20302028 [TBL] [Abstract][Full Text] [Related]
15. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen. Metser U; You J; McSweeney S; Freeman M; Hendler A AJR Am J Roentgenol; 2010 Mar; 194(3):766-71. PubMed ID: 20173157 [TBL] [Abstract][Full Text] [Related]
16. Combined FDG-positron emission tomography and computed tomography for the detection of ovarian cancer recurrence in an inguinal hernia sac. Díaz-Montes TP; Jacene HA; Wahl RL; Bristow RE Gynecol Oncol; 2005 Sep; 98(3):510-2. PubMed ID: 15992914 [TBL] [Abstract][Full Text] [Related]
17. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer. Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010 [TBL] [Abstract][Full Text] [Related]
18. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer. Arulampalam T; Costa D; Visvikis D; Boulos P; Taylor I; Ell P Eur J Nucl Med; 2001 Dec; 28(12):1758-65. PubMed ID: 11734912 [TBL] [Abstract][Full Text] [Related]
19. MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. Iyer VR; Lee SI AJR Am J Roentgenol; 2010 Feb; 194(2):311-21. PubMed ID: 20093590 [TBL] [Abstract][Full Text] [Related]
20. Imaging of gynecologic malignancies with FDG PET-CT: case examples, physiologic activity, and pitfalls. De Gaetano AM; Calcagni ML; Rufini V; Valentini AL; Gui B; Giordano A; Bonomo L Abdom Imaging; 2009 Nov; 34(6):696-711. PubMed ID: 18791682 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]